NCT00425191 - Taxotere Combinations as First Line Therapy for Locally Advanced Unresectable or Metastatic Non-small Cell Lung Cancer. | Biotech Hunter

Enrollment

165

Participants

Timeline

Start Date

July 31, 2002

Primary Completion Date

April 30, 2005

Conditions

Non-small Cell Lung Cancer

Interventions

DRUG

Docetaxel and Gemcitabine

Docetaxel: 40 mg/m², administered IV over 60 minutes (infusion drop by drop during the first five minutes) on day 1 and 8 immediately followed by Gemcitabine: 1200 mg/m2, administered IV over 30 minutes on day 1 and 8

DRUG

Docetaxel and Gemcitabine

Docetaxel: 50 mg/m², administered IV over 60 minutes (infusion drop by drop during the first five minutes) on day 1 and 15 immediately followed by Gemcitabine: 1600 mg/m2, administered IV over 30 minutes on day 1 and 15.

DRUG

Gemcitabine cisplatin followed by docetaxel

Gemcitabine: 1200 mg/m2, administered IV over 30 minutes on day 1 and 8 followed by Cisplatin 75 mg/m2, administered IV over 30-60 minutes on day 2

Trial Locations (1)

Unknown

Sanofi-Aventis, Milan